
Russian Chemical Bulletin p. 682 - 688 (1995)
Update date:2022-08-11
Topics:
Pleshakov, V. G.
Akimov, V. M.
Nava, E. Huipe
Lindeman, S. V.
Struchkov, Yu. T.
et al.
Based on thermogravimetric characteristics first obtained for the model 6H-indeno<1,2-b>quinoline, the scheme of thermal conversions of this compound in the temperature range 20-700 deg C has been proposed, and the limit of its thermal stability (ca. 300 deg C) has been determined.This temperature is recommended as the optimum for synthesizing fused benzoaza(diaza)fluorenes.Based on the results of X-ray structural analysis, the molecules of the studied indenoquinoline form centrosymmetric pairs, which are arranged in (110) layers.The molecules are orientationally disordered self-association of these molecules is similar to the ?-? association of fused heterocyclic systems with ?-excessive and ?-deficient fragments.It has been suggested that interferon-inducing and antitumor compounds with an annelated indenyl fragment have a common mechanism of action according to the intercalation model of stacking structures. - Key words: CH-acids; 6H-indeno<1,2-b>quinoline, heterogeneous catalytic dehydrogenation, thermogravimetric and X-ray structural analysis; interferon-inducing and antitumor intercalators; topological factor; stacking structures.
View More
Contact:+44 (0)2036089360-31
Address:Chanceryhouse,Chancery Lan
Shandong Topscience Biotech Co., Ltd.
Contact:0633-2619278
Address:No. 98 Lanshan West Road, Lanshan District, Rizhao, Shandong Province, P.R. of China
Yantai Derun Liquid Crystal Materials Co. Ltd.
website:http://www.ytderun.com
Contact:86-535-6300169
Address:ROOM 90, XIANGFU STREET, FUSHAN NEW-HIGH-TECH IDUSTRY ZONE, YANTAI
Jiangsu Wanlong Chemical Co., Ltd.
website:http://www.wanlongchem.com
Contact:+86-511-86810993 0086-511-8681 0888;
Address:Quanzhou Town, Danyang City, Jiangsu
website:http://www.chinabarton.com
Contact:+86-573-82719618
Address:No. 162 Fumin Road, Honghe Town,
Doi:10.1016/j.tet.2005.06.120
(2005)Doi:10.1021/j100342a039
(1989)Doi:10.1007/s10600-005-0159-y
(2005)Doi:10.1016/j.ijpharm.2010.05.035
(2010)Doi:10.1007/BF00471245
()Doi:10.1021/j100380a004
(1990)